Oral compositions provide delivery of cannabinoids to a subject. The oral compare chewable, fast- or slow-dissolving once placed in the mouth of a subject.

A soft chewable composition containing psyllium. The soft chewable composition can have from about 1% to about 55% psyllium and have a Hardness Parameter of greater than about 300 gf at a water activity of about 0.80 and less than about 10,000 gf at a water activity of about 0.50 as measured by the Texture Profile Analysis Method.

A nicotine oral delivery product contains a powder enclosed in a water insoluble pouch, wherein the pouch is permeable for saliva and therein dissolved parts of the powder, wherein the powder comprises at least (a) nicotine selected from the group consisting of tobacco, nicotine salts, nicotine base, stabilized nicotine, and mixtures thereof corresponding to 0.1 to 20 mg nicotine in the form of nicotine base and (b) a chewing gum composition. A method is provided for producing the nicotine oral delivery product.

A method for stabilize reduced glutathione using micronized curcumin, to provide a solid and liquid composition or formulation comprising a dispersion of the micronized curcumin. Also, a method for improving the oxidative stability of a peptide in a composition by adding micronized curcumin with the composition, and dispersing the micronized curcumin into the composition containing the peptide. The composition can include a chewing gum.

The invention relates to a chewing gum comprising at least a gum core comprising nicotine polacrilex, at least a one outer coating covering the core, comprising at least one sugar alcohol or mixtures of sugar alcohols and, at least a one portion fused onto the outer coating, wherein the portion comprises nicotine bitartrate or nicotine ditartrate dihydrate and at least one sugar alcohol or a mixture of sugar alcohols and at least one buffer present in the coating and/or in a portion fused to the coating.

An orally administrable chewing gum formulation is provided comprising a pharmaceutically acceptable gum base and particles of a pharmaceutical agent ranging in site from about 50 to about 2000 μm, wherein the formulation comprises about 0.5-30% by wt of the pharmaceutical agent particles. A liquid formulation comprising particles of a pharmaceutical agent is also provided.

A smokeless tobacco product or medicinal nicotine product includes nicotine and camphor dissolved in a non-flavored oily carrier. Preferably, the camphor is present in a concentration ranging from about 600 ppm to about 1300 ppm. Also disclosed are methods of making such products.

A pharmaceutical composition containing isomyosmine or a pharmaceutically acceptable salt thereof is administered to an individual in need thereof for treating a substance addiction, inclusive of affecting smoking substitution, eliminating cravings for tobacco and nicotine, or transitioning individuals away from smoking or the use of other tobacco products. In some examples, the therapeutic agent(s) are administered in a capsule, tablet, or lozenge. In other examples, the therapeutic agent(s) are administered via a chewing gum, inhalation spray, e-cigarette, nasal spray, or transdermal patch.

The invention provides a probiotic formulation that includes an LDH-deficient mutans streptococcus strain and an attenuated S. oralis strain. S. uberis strains can be included in the probiotic formulation. Such a probiotic formulation is suitable for persistently or permanently colonizing the oral cavity with beneficial bacteria,

A chewing gum composition comprising cannabinoids or derivatives thereof and nicotine in the form of nicotine polacrilex is provided. The chewing gum composition is formulated to provide rapid and controlled release of cannabinoids and nicotine during chewing. Methods to provide tobacco and/or cannabis smoking cessation using the chewing gum composition according to this invention are also provided.